《公司業績》藥明生物(02269.HK)中期純利25.35億人民幣增37.6% 不派息
藥明生物(02269.HK)公布6月止六個月中期業績,收益72.06億人民幣(下同),按年增加63.5%。錄得純利25.35億元,增長37.6%,每股盈利61分。不派中期息。
上半年,IND前服務收益26.38億元,增加8.1%;早期臨床開發服務收益12.84億元,增加42.7%;後期臨床開發服務及商業化生產收益31.52億元,增加63.5%。銷售及服務成本上升79.8%至37.93億元。期內,毛利34.13億元,增加48.6%;毛利率由52.1%降至47.4%。
收益增長高於毛利增長主要因去年同期是錄得極高利潤率的特殊時期,集團盡可能控制員工人數增長的情況下推進執行大量新的綜合項目。今年上半年,持續投資於人才的招聘及留任、產能擴張及全球佈局擴展以確保長期可持續增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.